S
Sridharan Gururangan
Researcher at University of Florida
Publications - 181
Citations - 11864
Sridharan Gururangan is an academic researcher from University of Florida. The author has contributed to research in topics: Bevacizumab & Glioma. The author has an hindex of 53, co-authored 179 publications receiving 10634 citations. Previous affiliations of Sridharan Gururangan include Duke University & Durham University.
Papers
More filters
Journal ArticleDOI
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
James J. Vredenburgh,Annick Desjardins,James E. Herndon,Jennifer Marcello,David A. Reardon,Jennifer A. Quinn,Jeremy N. Rich,Sith Sathornsumetee,Sridharan Gururangan,John H. Sampson,Melissa Wagner,Leighann Bailey,Darell D. Bigner,Allan H. Friedman,Henry S. Friedman +14 more
TL;DR: Bvacizumab and irinotecan is an effective treatment for recurrent glioblastoma multiforme and has moderate toxicity.
Journal ArticleDOI
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
James J. Vredenburgh,Annick Desjardins,James E. Herndon,Jeannette M. Dowell,David A. Reardon,Jennifer A. Quinn,Jeremy N. Rich,Sith Sathornsumetee,Sridharan Gururangan,Melissa Wagner,Darell D. Bigner,Allan H. Friedman,Henry S. Friedman +12 more
TL;DR: The combination of bevacizumab and irinotecan is an active regimen for recurrent grade III-IV glioma with acceptable toxicity and no central nervous system hemorrhages occurred.
Journal ArticleDOI
Novel mutations target distinct subgroups of medulloblastoma
Giles W. Robinson,Matthew Parker,Tanya A. Kranenburg,Charles Lu,Charles Lu,Xiang Chen,Li Ding,Li Ding,Timothy N. Phoenix,Erin Hedlund,Lei Wei,Xiaoyan Zhu,Nader Chalhoub,Suzanne J. Baker,Robert Huether,Richard W. Kriwacki,Natasha Curley,Radhika Thiruvenkatam,Jianmin Wang,Gang Wu,Michael Rusch,Xin Hong,Xin Hong,Jared Becksfort,Pankaj Gupta,Jing Ma,John Easton,Bhavin Vadodaria,Arzu Onar-Thomas,Tong Lin,Shaoyi Li,Stanley Pounds,Steven W. Paugh,David Zhao,Daisuke Kawauchi,Martine F. Roussel,David Finkelstein,David W. Ellison,Ching C. Lau,Eric Bouffet,Tim Hassall,Tim Hassall,Sridharan Gururangan,Sridharan Gururangan,Richard J. Cohn,Richard J. Cohn,Robert S. Fulton,Robert S. Fulton,Lucinda L. Fulton,Lucinda L. Fulton,David J. Dooling,David J. Dooling,Kerri Ochoa,Kerri Ochoa,Amar Gajjar,Elaine R. Mardis,Richard K. Wilson,James R. Downing,Jinghui Zhang,Richard J. Gilbertson +59 more
TL;DR: Modelling of mutations in mouse lower rhombic lip progenitors that generate WNT-subgroup tumours identified genes that maintain this cell lineage (DDX3X), as well as mutated genes that initiate (CDH1) or cooperate (PIK3CA) in tumorigenesis.
Journal ArticleDOI
Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog–Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032
Giles W. Robinson,Brent A. Orr,Gang Wu,Sridharan Gururangan,Tong Lin,Ibrahim Qaddoumi,Roger J. Packer,Stewart Goldman,Michael D. Prados,Annick Desjardins,Murali Chintagumpala,Naoko Takebe,Sue C. Kaste,Michael Rusch,Sariah Allen,Arzu Onar-Thomas,Clinton F. Stewart,Maryam Fouladi,James M. Boyett,Richard J. Gilbertson,Tom Curran,David W. Ellison,Amar Gajjar +22 more
TL;DR: Molecular analyses support the hypothesis that SMO inhibitor activity depends on the genomic aberrations within the tumor and should be advanced in SHH-MB studies.
Journal ArticleDOI
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis
Vijay Ramaswamy,Marc Remke,Eric Bouffet,Claudia C. Faria,Sébastien Perreault,Yoon Jae Cho,David Shih,Betty Luu,Adrian M. Dubuc,Paul A. Northcott,Ulrich Schüller,Sridharan Gururangan,Roger E. McLendon,Darell D. Bigner,Maryam Fouladi,Keith L. Ligon,Keith L. Ligon,Keith L. Ligon,Scott L. Pomeroy,Scott L. Pomeroy,Sandra E. Dunn,Joanna Triscott,Nada Jabado,Adam M. Fontebasso,David T.W. Jones,Marcel Kool,Matthias A. Karajannis,Sharon Gardner,David Zagzag,Sofia Nunes,José Pimentel,Jaume Mora,Eric S. Lipp,Andrew W. Walter,Marina Ryzhova,Olga Zheludkova,Ella Kumirova,Jad Alshami,Sidney Croul,James T. Rutka,Cynthia Hawkins,Uri Tabori,Kari Elise T. Codispoti,Roger J. Packer,Stefan M. Pfister,Stefan M. Pfister,Andrey Korshunov,Andrey Korshunov,Michael D. Taylor +48 more
TL;DR: Subgroup-specific differences in the location and timing of recurrence across medulloblastoma subgroups have potential treatment ramifications and intensified local (posterior fossa) therapy should be tested in the initial treatment of patients with SHH tumours.